| Novo Nordisk's ongoing international rollout and uptake of the oral Wegovy pill and Wegovy HD, expanding market access for GLP-1 treatments. | Second Half 2026, with Germany launch in September 2026 | 2026-09-01 | 2026-12-31 | This catalyst is crucial for the 'GLP-1 Long '26' theme as it signifies a major market expansion for a leading GLP-1 drug, attracting GLP-1 naive patients and driving significant revenue for Novo Nordisk. Successful international launches validate the broader oral GLP-1 market, impacting competitive dynamics and overall theme growth. | Theme | theme_composer | NVO, 4519.T | 3 | 0.0084 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 1.2286 | 2026-09-16 | False | 1 | 0.4589 | 67.2497 | | Theme composer | | |
| Alnylam Pharmaceuticals' announcement of clinical data from the Phase 1 trial of ALN-2232 for obesity and weight management. | Second Half 2026 | 2026-07-01 | 2026-12-31 | This catalyst is directly relevant to the 'RNA Fat Redistribution' theme, as ALN-2232 is Alnylam's first adipose-targeted RNAi therapeutic for obesity. Positive data would de-risk this asset and support Alnylam's expansion into the high-value obesity market, diversifying its pipeline beyond the TTR franchise. | Theme | theme_composer | ALNY | 3 | 0.0013 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.1943 | 2026-09-16 | False | 1 | 0.4075 | 59.7258 | | Theme composer | | |
| Arrowhead Pharmaceuticals is expected to release additional Phase 1/2 data for ARO-ALK7 in obesity and/or file a Clinical Trial Application (CTA) for a new obesity candidate. | Q4 2026 | 2026-10-01 | 2026-12-31 | Further clinical data for ARO-ALK7 and the advancement of a new obesity candidate validate Arrowhead's RNAi platform in cardiometabolic diseases and obesity, supporting the broader theme of innovative fat redistribution therapies. | Ticker | theme_composer | ARWR | 1 | 0.0002 | 1.18 | 1.0 | | 1.0 | 0.022 | 2026-09-16 | False | 1 | 0.0021 | 0.2493 | | Theme composer | | |
| European regulatory approval for Foundayo (chronic weight management and type 2 diabetes) following a positive CHMP opinion. | by year end | 2026-10-01 | 2026-12-31 | This approval is crucial for the anticipated global rollout of Foundayo in major markets in 2027, significantly expanding its international revenue potential. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_10dadbeb | 2026-10-29 |
| Readout of Foundayo Phase 3 trial in obstructive sleep apnea. | later this year | 2026-10-01 | 2026-12-31 | Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_48d9403d | 2026-08-05 |
| U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes. | later this year | 2026-10-01 | 2026-12-31 | This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_696cb569 | 2026-08-05 |
| Launch of Orforglipron in a few international markets (e.g., UAE). | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_cf82d1b5 | 2026-02-04 |
| Potential U.S. regulatory approval for cemdisiran in generalized myasthenia gravis, a partnered product with Regeneron. | Q4 2026 for decision, late 2026 or early 2027 for launch | 2026-10-01 | 2027-03-31 | Approval would enable commercialization, leading to potential milestone payments and royalties for Alnylam, contributing to collaboration and royalty revenue. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ALNY (ticker) | ALNY_e966b7db | 2026-02-12 |
| Release of Phase 1 clinical data for ALN-HTT02 (Huntington's disease program). | second half of the year | 2026-07-01 | 2026-12-31 | Data on huntingtin protein lowering and safety are crucial for de-risking this program, which targets a devastating disease with no approved therapies, potentially accelerating its development and impacting long-term valuation. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ALNY (ticker) | ALNY_1f8d0ad4 | 2026-02-12 |
| Release of Phase 1 clinical data for ALN-2232 (ACVR1C targeting for obesity & weight management). | second half of the year | 2026-07-01 | 2026-12-31 | Positive data would de-risk the program, demonstrating its potential for durable weight loss and addressing unmet needs in the overweight/obesity and diabetes space, impacting long-term valuation. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ALNY (ticker) | ALNY_6acd0085 | 2026-02-12 |
| Readout of Phase 3 CARDIO-TTRansform study results for Ionis Pharmaceuticals' eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). | H2 2026 | 2026-07-01 | 2026-12-31 | Positive results could introduce a new competitive TTR silencer into the ATTR-CM market, potentially impacting Amvuttra's market share, pricing dynamics, and overall TTR franchise growth. | Theme | | | | | | | | | | | | | | | earnings_transcript | ALNY (ticker) | ALNY_5d72b867 | 2026-02-12 |
| Release of Phase 1 and 2 clinical data from the ALN-6400 program (targeting plasminogen for bleeding disorders). | second half of the year | 2026-07-01 | 2026-12-31 | Positive data would de-risk the program, supporting its 'pipeline-in-a-product' potential and future development in a range of bleeding disorders, impacting long-term valuation. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ALNY (ticker) | ALNY_94ae948c | 2026-02-12 |
| FDA regulatory decision for CagriSema in the U.S. for obesity. | at the end of 2026 | 2026-10-01 | 2026-12-31 | Approval would introduce a new, potentially highly effective obesity treatment, strengthening Novo Nordisk's pipeline and competitive position. | Ticker | | | | | | | | | | | | | | | earnings_transcript | NVO (ticker) | NVO_71e5b33d | 2026-05-06 |
| FDA decision on the New Drug Application (NDA) for cemdisiran, an siRNA targeting C5, in generalized myasthenia gravis (gMG). | November of this year | 2026-11-01 | 2026-11-30 | Potential approval would introduce a highly differentiated treatment option for gMG patients with a convenient quarterly subcutaneous dosing profile, expanding Regeneron's rare disease portfolio. | Ticker | | | | | | | | | | | | | | | earnings_transcript | REGN (ticker) | REGN_0f639ad7 | 2026-07-30 |
| FDA approval of the EYLEA HD prefilled syringe. | before the end of the year | 2026-10-01 | 2026-12-31 | This product enhancement is expected to drive even further adoption of EYLEA HD, strengthening its competitive position and contributing to sales growth. | Ticker | | | | | | | | | | | | | | | earnings_transcript | REGN (ticker) | REGN_76369989 | 2026-07-30 |
| Initiation of multiple Phase III studies for olatorepatide in patients with obesity and in patients with obesity and type 2 diabetes. | later this year | 2026-10-01 | 2026-12-31 | Marks significant progress in Regeneron's obesity portfolio, positioning the company to enter a high-growth market with a potentially differentiated dual GLP-GIP receptor agonist. | Ticker | | | | | | | | | | | | | | | earnings_transcript | REGN (ticker) | REGN_07f81147 | 2026-07-30 |
| Release of clinical data from the 600-milligram monthly dosing cohort of the RestorAATion-2 trial for WVE-006 in Alpha-1 Antitrypsin Deficiency. | second half of this year | 2026-09-01 | 2026-12-31 | This data will help inform the optimal dose regimen for WVE-006 and provide further evidence of its therapeutic profile, which is crucial for its registrational plans and potential accelerated approval. | Ticker | | | | | | | | | | | | | | | earnings_transcript | WVE (ticker) | WVE_3a372b71 | 2026-07-30 |
| Clinical Trial Application (CTA) submission for WVE-008 for the treatment of homozygous PNPLA3 I148M liver disease. | later this year | 2026-09-01 | 2026-12-31 | This submission marks the advancement of Wave's second RNA editing candidate into clinical development, expanding its pipeline and validating the platform's broader applicability in addressing high unmet needs in liver diseases. | Ticker | | | | | | | | | | | | | | | earnings_transcript | WVE (ticker) | WVE_a34877eb | 2026-07-30 |
| Initiation of additional Phase II clinical trials for WVE-007, evaluating its potential in combination with incretins and as a post-incretin maintenance therapy for obesity. | later this year | 2026-09-01 | 2026-12-31 | These trials expand the development program for WVE-007 into new, commercially significant market segments, potentially differentiating it from existing obesity treatments and enhancing its market opportunity. | Ticker | | | | | | | | | | | | | | | earnings_transcript | WVE (ticker) | WVE_29e0b824 | 2026-07-30 |
| Release of additional Phase I INLIGHT clinical data for WVE-007, specifically including results from the 600-milligram cohort. | this year | 2026-09-01 | 2026-12-31 | This data will provide further insights into the durability and efficacy of WVE-007 at a higher dose, which could strengthen its competitive profile and inform future development strategies in obesity. | Ticker | | | | | | | | | | | | | | | earnings_transcript | WVE (ticker) | WVE_8fe27c5d | 2026-07-30 |
| Submission of a New Drug Application (NDA) for accelerated approval of N531 with a monthly dosing regimen for Duchenne Muscular Dystrophy (DMD). | in 2026 | 2026-01-01 | 2026-12-31 | An NDA submission would be a significant step towards commercialization for N531, potentially offering a new treatment option for DMD patients and generating revenue for Wave. | Ticker | | | | | | | | | | | | | | | earnings_transcript | WVE (ticker) | WVE_2167fb27 | 2026-02-26 |
| Initiation of new clinical trials evaluating WVE-007 as an incretin add-on and as a post-incretin maintenance therapy. | in 2026 | 2026-01-01 | 2026-12-31 | These trials could position WVE-007 as a complementary or alternative therapy to GLP-1s, addressing unmet needs in tolerability, muscle preservation, and long-term weight management, potentially expanding its commercial potential. | Ticker | | | | | | | | | | | | | | | earnings_transcript | WVE (ticker) | WVE_87860d6a | 2026-02-26 |
| Receipt of additional milestone payments from the research collaboration with GSK as programs advance. | in 2026 and beyond | 2026-01-01 | 2026-12-31 | These milestone payments provide non-dilutive funding, validate Wave's PRISM platform, and contribute to the company's cash runway, supporting its R&D efforts. | Ticker | | | | | | | | | | | | | | | earnings_transcript | WVE (ticker) | WVE_588bde35 | 2026-02-26 |
| Lilly Innovation Day. | December 7th | 2026-12-07 | 2026-12-07 | This event is expected to provide more detailed insights into Lilly's pipeline, potentially revealing new material information about future growth drivers and strategic priorities. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_a24ab55b | 2026-10-29 |
| U.S. regulatory submission (BLA pathway) for retatrutide. | Q1 2027 | 2027-01-01 | 2027-03-31 | This submission is a critical step towards bringing the highly efficacious triple agonist, retatrutide, to market, potentially solidifying Lilly's leadership in cardiometabolic health with a drug demonstrating unprecedented weight loss. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_a075099b | 2026-10-29 |